Moxetumomab Pasudotox-tdfk: A Targeted Therapy for Recurrent Hairy Cell Leukemia

US Brand Name(s) for Moxetumomab pasudotox-tdfk: Lumoxiti

For  Detailed scientific definition Definition from the NCI Drug Dictionary

Use of Moxetumomab pasudotox-tdfk in Cancer Treatment

It is to treat the following conditions:

Hairy cell leukemia that has relapsed or has become resistant to therapy (does not respond to treatment). It is for individuals who have had at least two systemic treatments, one of which must be a purine nucleoside analog.

Moxetumomab Pasudotox-tdfk

A summary of key facts regarding this medication in layman’s terms, which may contain the following:

  • Cautions about this medicine
  • What is the use and how?
  • Whom should you consult before taking it?
  • What you should know about it before using it?
  • Other drugs that might interact with it
  • Possible negative effects

Drugs are frequently under research to see whether they can assist treat or prevent conditions other than those already prevalent. This patient information leaflet covers uses which have been under authorization. Much of the material, though, might also apply to authorized uses that are being investigated.